We also need a robust pipeline of discovery thatll lead to new drug candidates for all different kinds of infections. So the limited population idea and the streamlining of Clinical Trials which wouldnt just decrease the time frame, it also decreases the cost and the, you know, the number of people needed, so it would do a number of things, that is one thing that we can do at fda that we think would be beneficial and would be beneficial for patients, but its not going to fix this problem we have of investment. Thank you, mr. Chairman. I yield back. I think that concludes this round of questioning. Well have followup questions, im sure, from members. Well send them to you and ask that you please respond. But, again, dr. Woodcock, you are a terrific witness. Thank you for your being so forthright, clear in your answers, and we will now take a three minute recess as we set up for the second panel. Thank you. The subcommittee willw reconvene on our second panel. Today we have, and ill them
Were offering a tool but you aught to beware, and be a stewardship in this tool. We have worked with new guidances to try to lower the cost of a Development Program. So that the pipeline can be, you know, more robust. You know, on the issue of judicious use and stewardship and i hear the words that are set on that. But you know, you talk about using things outside their area of indication. We tend to think of the world in which we live. But im from texas and im just a little bit south of texas theres a dirent world where there is not a prescription requirement and you simply go to the pharmacy and say, i need this. And the pharmacist may direct them to a particular drug or may just simply come in with a recommendation from a Family Member and make that purchase. So it is an obviously harder to control that with the jurisdiction of the United States where it is happening right outside. Is that correct . Totally agree. Everybody is outside with modern air travel. And so we are getting so
Were offering a tool but you aught to beware, and be a stewardship in this tool. We have worked with new guidances to try to lower the cost of a Development Program. So that the pipeline can be, you know, more robust. You know, on the issue of judicious use and stewardship and i hear the words that are set on that. But you know, you talk about using things outside their area of indication. We tend to think of the world in which we live. But im from texas and im just a little bit south of texas theres a dirent world where there is not a prescription requirement and you simply go to the pharmacy and say, i need this. And the pharmacist may direct them to a particular drug or may just simply come in with a recommendation from a Family Member and make that purchase. So it is an obviously harder to control that with the jurisdiction of the United States where it is happening right outside. Is that correct . Totally agree. Everybody is outside with modern air travel. And so we are getting so
A version of this article was first published December 14, 2020, by HCPro s
Q: How does CMS define a shoppable service ? What information needs to be included in the list of 300 shoppable services required by the Hospital Price Transparency final rule?
A: A shoppable service is typically a nonurgent service a patient can schedule in advance, Hartstein said. The list of shoppable services must include 70 services selected by CMS and 230 services selected by the hospital for a total of 300 services. If your hospital doesn’t offer one or more of the CMS-selected services, you must indicate that the service isn’t offered at your hospital, said